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INTRODUCTION
CD99 is a 32-kDa cell surface sialoglycoprotein, which is
expressed in a wide variety of human cells. Functionally, CD99
is considered to act as an adhesion molecule or as a signal-
transducing molecule (1, 2). Since original report that demon-
strated its diagnostic utility in Ewing’s sarcoma/primitive
neuroectodermal tumor (3), CD99 expression has been demon-
strated in a broad range of normal and neoplastic cells (4-10).
In hematologic neoplasms, CD99 expression is well correlat-
ed with TdT positivity (11) and has been observed in T- and
B-lymphoblastic lymphomas/leukemias, 55% of chloromas,
43% of acute myelogenous leukemias, and chronic myeloge-
nous leukemias in blastic crisis (12). While CD99 is consid-
ered a useful marker for detecting lymphoblastic neoplasms,
previous studies on mature T- and B cell non-Hodgkin’s lym-
phomas (NHLs) have reported discordant results concerning
the spectrum of CD99-positivity (11, 13, 14). In this study
we examined CD99 immunoreactivity in a variety of NHL,
including 21 lymphoblastic lymphomas/leukemias, 87 mature
B-cell lymphomas, and 74 mature T and NK cell lymphomas. 
MATERIALS AND METHODS
Case selection
During the period from January 1996 to April 2004, 182
patients diagnosed as having non-Hodgkin’s lymphoma were
randomly selected at Samsung Medical Center, Seoul, Korea.
The selected cases comprised 21 lymphoblastic lymphomas/
leukemias, 37 diffuse large B cell lymphomas, 18 Burkitt’s
lymphomas, 12 follicular lymphomas, 11 small lymphocytic
lymphomas, 9 mantle cell lymphomas, 28 NK/T-cell lym-
phomas, 8 angioimmunoblastic T-cell lymphomas, 23 periph-
eral T-cell lymphomas, and 15 anaplastic large cell lymphomas.
Clinical and laboratory records including a chromosomal study
were reviewed.
Histologic examination
Hematoxylin eosin-stained slides were reviewed in all cases
and the diagnosis was made based on recent WHO classifi-
cation (15).
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Immunoreactivity of CD99 in Non-Hodgkin’ s Lymphoma
: Unexpected Frequent Expression in ALK-positive Anaplastic Large Cell
Lymphoma
To verify the spectrum of CD99-expressing lymphoid malignancy, an immunohisto-
chemical study for CD99 was carried out in 182 cases of non-Hodgkin's lymphoma,
including 21 lymphoblastic lymphomas, 11 small lymphocytic lymphomas, 9 mantle
cell lymphomas, 12 follicular lymphomas, 37 diffuse large B cell lymphomas, 18
Burkitt's lymphomas, 28 NK/T-cell lymphomas, 8 angioimmunoblastic T-cell lym-
phomas, 23 peripheral T-cell lymphomas, unspecified, and 15 systemic anaplastic
large cell lymphomas. CD99 was positive in all T-lymphoblastic lymphomas and in
60% of B-lymphoblastic lymphomas. Majority of T and NK cell lymphomas were
negative for CD99, except anaplastic large cell lymphomas (ALCLs). Eight of 15
cases (54%) of ALCLs reacted with anti CD99 antibody. Seven of 10 (70%) ALK
positive ALCLs expressed CD99, whereas only 1 of 5 (20%) ALK negative ALCLs
were positive. Of the mature B-cell lymphomas, 5.4% (2/37) of diffuse large B cell
lymphomas and 11.1% (2/18) of Burkitt's lymphomas expressed CD99. In conclu-
sion, CD99 is infrequently expressed in mature B and T cell lymphomas, except
ALK-positive ALCL. High expression of CD99 in ALK-positive ALCL is unexpected
finding and its biologic and clinical significances have yet to be clarified.
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Immunohistochemical studies
Paraffin sections were stained with monoclonal CD99 anti-
body, 12E7 (1:40, DAKO, Carpinteria, CA, U.S.A.) in an
automated staining system. Antigen retrieval was conducted
in a microwave oven in citrate buffer at pH 6.0 before incu-
bation with primary antibody. The tumors were considered
immunoreactive for CD99 if diffuse cell membrane staining
was observed in more than 70% of tumor cells. Focal or weak
staining was interpreted as negative. In addition, paraffin sec-
tions were stained with ALK1 monoclonal antibody at a dilu-
tion of 1:40 (DAKO, Glostrup, Denmark), polyclonal anti-
body for CD3 (1:200, Novocastra, U.K.), monoclonal anti-
body for CD20 (1:500, Novocastra), monoclonal antibody
for bcl-2 (1:40, DAKO), polyclonal antibody for bcl-6 (1:40,
Santacruz, California, U.S.A.), monoclonal antibody for CD10
(1:50, Novocastra, U.K.), monoclonal antibody for CD56 (1:
20, Monosan, New Zealand), monoclonal antibody for CD30
(1:30, DAKO, Glostrup, Denmark), and with monoclonal
antibody for CD21 (1:25, DAKO, Glostrup, Denmark).
Western blot analysis to verify CD99 expression
To verify CD99 expression in anaplastic large cell lym-
phoma, western blot analysis was performed in one case of
anaplastic large cell lymphoma of which fresh tumor tissue
was available. For the positive control, lymphoblastic lym-
phoma was used. Monoclonal CD99 antibody, 12E7 (DAKO,
Carpinteria, CA) was applied at a dilution of 1:1,000.
RESULTS
The results of immunohistochemical staining for CD99
are summarized in Table 1.
CD99 was positive in 100% of T-lymphoblastic lympho-
mas, but in only 60% of B-lymphoblastic lymphomas/leu-
kemias. The majority of mature T and NK cell lymphomas
were negative for CD99, except anaplastic large cell lym-
phomas. Fifty-four percent (8/15) of systemic ALCLs react-
ed with anti CD99 antibody. ALK positive tumors expressed
CD99 more frequently than ALK negative tumors; 7 of 10
(70%) ALK positive ALCLs expressed CD99 (Fig. 1), whereas
only 1 of 5 (20%) ALK negative ALCLs were positive. The
intensity of CD99 in ALCL was rather weaker than that of
lymphoblastic lymphoma, but cytoplasmic membrane stain
of tumor cells was obvious which was in accord with the result
of western blot analysis (Fig. 2). Of the mature B cell lym-
phomas, 5.3% (2/37) of diffuse large B cell lymphomas and
11.1% (2/18) of Burkitt's lymphomas were positive for CD
99. All follicular lymphomas, small lymphocytic lymphomas,
and mantle cell lymphomas were negative for CD99. 
Of the 2 cases of CD99-positive diffuse large B cell lym-
phoma, one was a 51-yr-old man who presented with axil-
lary lymph node enlargement. This tumor was composed of
large cells, which were positive for CD20, bcl-6, MUM-1,
and EBV ISH, and negative for CD3 and CD10. The second
patient was a 56-yr-old female who presented with an enlarged
neck lymph node; tumor cells were large, had a diffuse appea-
rance, and were positive for CD20 and bcl-6, and negative
for CD10, bcl-2, MUM-1, and EBV ISH.
In the two CD99-positive cases of Burkitt’s lymphomas,
one patient was a 78-yr-old man who present with a stom-
ach lesion. Tumor cells showed strong bcl-6 and CD20 expres-
sion, but were negative for bcl-2, and had a Ki-67 labeling
index more than 99%. The other patient was 65-yr-old man
with a retroperitoneal tumor, which was negative for TdT
and positive for CD79a and CD20 with a Ki-67 labeling
index of 90%. In this case bone marrow metastasis was iden-
tified at the initial diagnosis and a chromosomal study revealed
t(8:14). Microscopically tumor cells were monotonous with
round to oval nuclei and a prominent nuclear membrane. Nucle-
oli were prominent and ranged from 2 to 5 per nucleus. Occa-
sional tumor cells had a centrally located single prominent
nucleolus resembling an immunoblast. The chromatin was
coarse and irregularly distributed.
DISCUSSION
CD99 is a 32-kDa transmembrane sialoglycoprotein that
is expressed on many types of human cells. However, despite
its broad distribution CD99 is only strongly expressed in
relatively a few cell types, such as bone marrow progenitor
cells, pancreatic islet cells, granulosa cells of the ovary, and
Leydig and Sertoli cells of the testis and ependyma (3, 7, 16).
CD99 was originally described as a diagnostically useful
marker for Ewing’s sarcoma/primitive neuroectodermal tumor
(3), but CD99 immunoreactivity has also been documented
in a variety of other tumors, including sex cord tumors of the
testis and ovary, synovial sarcoma, chondrosarcoma, and neu-
Cases CD99 positive 
cases/ total no.
%
positive
T-lymphoblastic lymphoma 16/16 100
B-lymphoblastic lymphoma 3/5 60
NK/T-cell lymphoma 0/28 0
Angioimmunoblastic T-cell lymphoma 0/8 0
Peripheral T-cell lymphoma 0/23 0
Systemic anaplastic large cell lymphoma 8/15 54
ALK positive 7/10 70
ALK negative 1/5 20
Diffuse large B-cell lymphoma 2/37 5
Burkitt's lymphoma 2/18 11
Follicular lymphoma 0/12 0
Small lymphocytic lymphoma 0/11 0
Mantle cell lymphoma 0/9 0
Table 1. Summary of CD99 immunoreactivity954 C.O. Sung, Y.H. Ko, S. Park, et al.
roendocrine tumors (6-8). Moreover, within the hematopoi-
etic system CD99 expression is strongly correlated with TdT
expression, in addition it is highly expressed in early CD34+
precursors, which is in line with the maturation process (16,
17). In hematologic neoplasms, CD99 expression has been
observed in T-and B-lymphoblastic lymphomas/leukemias,
chloroma, acute myelogeneous leukemia, and chronic myel-
ogeneous leukemia in blastic crisis (12, 13). 
The expression of CD99 in non-Hodgkin’s lymphomas,
other than those of the lymphoblastic type has become the
subject of debate. One study had reported a negative reaction
in all NHLs, other than lymphoblastic lymphoma (9), whilst
the other had described only weak, non-uniform, poorly local-
ized cytoplasmic staining in a minority of cases (13). Varta-
nian et al. (14), using a heat-induced epitope retrieval (HIER)
technique, reported that a variety of malignant lymphomas,
other than the lymphoblastic type, show significant CD99
reactivity. However, Robertson et al. (11), also using HIER,
found that positive CD99 staining was restricted to lym-
phoblastic disorders, and ascribed this discrepancy to tech-
nical differences. The present study, also using HIER, revealed
distinct membranous CD99 staining in a few cases of NHL
of the mature phenotype, and unexpectedly high expression
in ALK-positive ALCLs. Twenty percent of ALK-negative
ALCLs expressed CD99, and this rose to 70% in ALK-posi-
tive ALCLs.
How the high expression of CD99 in ALK positive ALCLs
be explained? Though there appears to be no clear-cut answer
to this question, present data suggest that ALK protein may
play a role. CD30 is a member of the tumor necrosis factor
receptor (TNFR) superfamily and one of essential findings
for the diagnosis of ALCL and Hodgkin’s disease (18, 19). In
Hodgkin’s disease (HD), constitutively activated NF- B by
either EBV LMP-1 gene or CD30, down-regulates the expres-
sion of CD99 and the repression is restored by the inhibition
of NF- B activity (20). In ALK-positive ALCL, NF-  B acti-
Fig. 1. (A) Anaplastic large cell lymphoma. H & E stain (×400). (B) Anaplastic large cell lymphoma, CD30 expression (×100). (C) Anaplstic
large cell lymphoma, ALK protein (×100). (D) Anaplastic large cell lymphoma, CD99 expression (×100). (E) Anaplastic large cell lymphoma.
Higher magnification of CD99 immunostain (×400).
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Fig. 2. Western blot analysis using CD99
antibody shows positive band of 33 kDa
in size. N, negative control; 1, anaplas-
tic large cell lymphoma; P, positive con-
trol (lymphoblastic lymphoma).CD99 in Non-Hodgkin's Lymphoma 955
vation is not observed in the presence of equivalent levels of
CD30 expression (21) because NPM-ALK oncoprotein abro-
gates CD30 signaling and constitutive NF- B activation (22).
The functional roles of CD99 expressed in ALCL are un-
known. The CD99 signal enhances Fas-mediated apoptosis
in the human leukemic cell line (23). Engagement of distinct
epitopes on CD99 rapidly induces T cell death by a novel
caspase-independent pathway through reorganization of cyto-
skeleton (24). Because ALK-positive ALCLs show higher apop-
tosis rate and higher levels of active procaspase 3 and proapop-
totic Bcl-2 family proteins such as BAX and BCL-XS than
ALK-negative ALCLs, it is conceivable that CD99 works on
apoptotic cell death in ALK-positive ALCLs (25, 26). 
In summary, present study demonstrates that CD99 exp-
ressed frequently in ALK-positive ALCL, but not in other
mature T and NK cell lymphoma. The result expands our
understanding on the spectrum of CD99-positive neoplasm
although its biologic and clinical significance remained to
be clarified.
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